Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Summary of basic and diluted earnings per share (Details)

v3.23.1
Summary of basic and diluted earnings per share (Details) - GBP (£)
 6 Months Ended 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Loss for the year £ 1,400,000 £ 13,600,000 £ (1,389,706) £ (13,575,925) £ (5,457,916)
Basic and diluted weighted average number of shares outstanding [1]     687,199 390,585 378,481
Basic and diluted loss per share     £ (2.02) £ (34.76) £ (14.42)
[1] On November 18, 2022, TC BioPharm (Holdings) plc completed a reverse stock split of one (1) new share for every fifty (50) existing shares effective November 21, 2022. As a result of the share split, all references in these financial statements and accompanying notes to units of ordinary shares or per share amounts are reflective of the reverse share split for all periods presented. In addition, the exercise prices and the numbers of ordinary shares issuable upon the exercise of any outstanding options to purchase ordinary shares were proportionally adjusted pursuant to the respective anti-dilution terms of the share-based payment plans.